16 March 2022 in Revista de la Facultad de Medicina Humana
Bone marrow transplantation, currently known as hematopoietic stem cell transplant (HSCT), involves the infusion of stem cells healthy hematopoietic cells to patients with dysfunctional bone marrow, diminished or compromised by hematological neoplasms. Since its rst exploration in humans in the 1950s based on the results obtained in animal models, more than one million procedures have now been performed in Europe and collaborating countries. Early detection of complications and histocompatibility typing (HLA) with which potential donors can be better-selected thanks to an international donor registry network of bone marrow and the advancement of technology in terms of support treatment.
2 September 2025 in Revista Peruana de Medicina Experimental Y Salud Pública
Objective. To determine mortality and associated factors in patients who received an allogeneic hematopoietic stem cell transplant at the Hospital Nacional Edgardo Rebagliati Martins, between January 2017 and December 2022. Materials and methods. A retrospective cohort study was conducted on patients who underwent allogeneic hematopoietic stem cell transplantation (HSCT) between 2017 and 2022. Death at one hundred days and two years, and its associated factors, were evaluated. Proportional Cox regression models were used. Results. 342 post-HSCT patients were included, with a median age of 23 years (interquartile range: 10 to 39), of whom 53.5% were women. The most frequent diagnosis for the transplant was acute lymphoblastic leukemia at 54.1%. Mortality in the first 100 days post-HSCT was 8.2%, and at two years was 30.4%. In the multivariate regression at one hundred days, factors associated with a higher risk of mortality were age over 50 years (HRa: 6.97; 95% CI: 1.18−41.23), being a recipient of a haploidentical transplant (HRa: 3.57; 95% CI: 1.13−11.24), and sepsis as a complication (HRa: 68.78; 95% CI: 19.32−244.84). In the two-year analysis, acute myeloid leukemia (1.72; IC 95%: 1.08-2.74), haploidentical transplant (HRa:1.81; 95%CI: 1.21-2.72), and disease relapse (HRa: 4.17; 95%CI%: 2.75-6.31) were associated with a higher risk of death. Conclusions. The mortality found was low and similar to that of countries with higher incomes; however, it is necessary to formulate interventions that reduce the incidence of modifiable factors such as sepsis.
30 October 2022 in ONKORESEARCH
Background: The COVID-19 pandemic has led to unprecedented economic and health vulnerability and inequities globally. Objective: This study examines the out-of-pocket expenses assumed by parents of children and adolescents with cancer in Peru during the COVID-19 pandemic and compares them to those corresponding to the pre-COVID era. Materials and methods: We conducted a cross-sectional survey of parents and caregivers of pediatric cancer patients who were cared for in public and private institutions between October and November 2020. All of them gave their consent before completing the survey. Respondent parents of children diagnosed before March 2020 were considered the pre-COVID-19 pandemic group, whereas if the definitive diagnosis was made after this date, it was classified as part of the COVID-19 group. Results: A total of 222 parents and caregivers of children with cancer responded to the survey. Almost half of the respondents lived in Lima. The average monthly family income was USD 388.4 and USD 314.7 before and during the COVID-19 pandemic. The average expenditure was USD 487.0 (SD, 453.5) and USD 415 (SD, 414.5) before and during the COVID-19 pandemic, before the cancer diagnosis. The average expenditure was USD 454.6 (SD, 406.7) and USD 387.5 (SD, 323.4) before and during the COVID-19 pandemic after a cancer diagnosis. In the COVID-19 group, the rate of catastrophic expenditure on these families was 86% before the definitive diagnosis and 75% after the cancer diagnosis. According to the type of cancer, families with a child diagnosed with a solid tumor had significantly higher out-of-pocket expenses than a leukemia than those with a child with leukemia prior to their diagnosis. Conclusion: Our study suggests that high out-of-pocket health expenses were frequent in families with a child with cancer in Peru during the COVID-19 pandemic. It is possible to infer that this situation was aggravated by the decrease in economic income of most families due to the disruption of formal and informal employment.